Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder

Zazula, Robson; Dodd, Seetal; Dean, Olivia; Berk, Michael; Bortolasci, Chiara C.; Verri, Waldiceu A.; Vargas, Heber Odebrecht; Nunes, Sandra

doi:10.1080/15622975.2021.1925152

Cited by 14 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, patients who showed a better lithium response had significantly decreased TNF-α levels ( Guloksuz et al, 2012 ; Remlinger-Molenda et al, 2012 ). Conversely, other studies showed that a subset of patients who were following treatment with antipsychotics or lithium did not show statistical differences in TNF-α levels compared to controls ( Zazula et al, 2022 ), as in our cohort, made up of patients under antipsychotic treatment.…”

Section: Discussioncontrasting

confidence: 79%

Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients

Fernández-Pereira,

Penedo,

Alonso-Núñez

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Bipolar disorder (BD) is a recurrent and disabling psychiatric disorder related to low-grade peripheral inflammation and altered levels of the members of the insulin-like growth factor (IGF) family. The aim of this study was to evaluate the plasma levels of IGF-2, insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, IGFBP-5, IGFBP-7, and inflammatory markers such as tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β).Methods: We used the Young Mania Rating Scale (YMRS) to determine the severity of the symptomatology, while proteins were measured by enzyme-linked immunosorbent assay (ELISA). We included 20 patients with BD who suffered a manic episode and 20 controls. Some BD patients (n = 10) were evaluated after a period (17 ± 8 days) of pharmacological treatment.Results: No statistical difference was found in IGF-2, IGFBP-1, IGFBP-7, TNF-α, and MIP-1β levels. However, IGFBP-3 and IGFBP-5 levels were found to be statistically decreased in BD patients. Conversely, the MCP-1 level was significantly increased in BD patients, but their levels were normalized after treatment. Intriguingly, only IGFBP-1 levels were significantly decreased after treatment. No significant correlation was found between the YMRS and any of the proteins studied either before or after treatment or between IGF proteins and inflammatory markers.Discussion: To some extent, IGFBP-3 and IGFBP-5 might be further explored as potential indicators of treatment responsiveness or diagnosis biomarkers in BD.

show abstract

Section: Discussioncontrasting

confidence: 79%

Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients

Fernández-Pereira,

Penedo,

Alonso-Núñez

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Chronic inflammation plays a role in the pathophysiology of many psychiatric diseases including affective disorders and schizophrenia [37]. Chronic inflammation may impair mood, cognition, motivation, appetite and sleep in patients with affective disorders [38,39]. One hypothesis is that inflammatory substances reveal the destabilization of the brain function, effected with environmental factors and, accordingly contribute to the presentation of mood symptoms [40].…”

Section: Discussionmentioning

confidence: 99%

Characteristics of platelet-associated parameters and their predictive values in Chinese patients with affective disorders

Wei

Feng²,

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

Objective Platelets are increasingly considered to play an important role in inflammation and are being regarded as a putative bridge linking mental diseases and inflammatory response. Platelet-associated haematological parameters including mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), systemic immune-inflammation index (SII), platelet to lymphocyte ratio (PLR), platelet to albumin ratio (PAR) and red blood cell distribution width (RDW) to platelet ratio (RPR), have been recently investigated as simple, easily available, and inexpensive inflammatory markers. In this study, we aimed is to use large-scale clinical data to study platelet parameters in patients with affective disorders, to further investigate the predictive power of platelet parameters for major depressive disorder (MDD) and bipolar disorder (BD). Methods The retrospective, naturalistic, cross-sectional study analysed the data of 14,007 Chinese affective disorder patients, including 4,801 patients with first-episode MDD, 4,098 patients with recurrent MDD, 3,444 patients with BD manic episodes and 1,664 patients with BD depressive episodes. Meanwhile, 6,847 healthy subjects were served as the control group. The differences in the MPV, PDW, PCT, SII, PLR, PAR, RPR and albumin among different groups were compared, and the contributing factors for the occurrence of MDD or BD were analysed. Results There were significant differences in MPV, PDW, PCT, SII, PLR, RPR and albumin values among the study groups. In the subjects, patients experiencing BD manic episodes had the highest mean values of MPV and SII, patients experiencing BD depressive episodes had the lowest mean values of platelet counts and PAR, and patients with MDD had the highest mean values of PLR and RDW. The levels of MPV, PDW and albumin were independently correlated with MDD and BD, and they are important predictors for differentiating patients with MDD or BD from healthy controls. Conclusions Our study demonstrated that different affective disorders have unique platelet parameter variation patterns, highlighting the role of platelet parameters and systemic inflammation in the pathophysiology of MDD and BD.

show abstract

“…Studies have shown that levels of soluble tumor necrosis factor receptor 2 (sTNFR2) in plasma are associated with hippocampal volume and cognitive performance in SCZ ( Kudo et al, 2018 ). Other studies have reported TNF variables during the neural progression of BD, suggesting that circulating levels of TNF molecules partially mediate the relationship between prior severe mood episodes and executive functioning in BD, and may serve as novel cognitive interventions ( Millett et al, 2020 ; Zazula et al, 2022 ). Circadian dysregulation in ASD is strongly associated with elevated TNF levels and immune-inflammatory activity, leading to sleep disturbances and cognitive and behavioral changes ( da Silveira Cruz-Machado et al, 2021 ).…”

Section: Proinflammatory Cytokines and Neurotrophinsmentioning

confidence: 99%

Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention

Wang

Meng

Liu

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Psychiatric diseases, such as schizophrenia, bipolar disorder, autism spectrum disorder, and major depressive disorder, place a huge health burden on society. Cognitive impairment is one of the core characteristics of psychiatric disorders and a vital determinant of social function and disease recurrence in patients. This review thus aims to explore the underlying molecular mechanisms of cognitive impairment in major psychiatric disorders and identify valuable biomarkers for diagnosis, treatment and prevention of patients.

show abstract

Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder

Cited by 14 publications

References 45 publications

Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients

Plasma IGFBP-3 and IGFBP-5 levels are decreased during acute manic episodes in bipolar disorder patients

Characteristics of platelet-associated parameters and their predictive values in Chinese patients with affective disorders

Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention

Contact Info

Product

Resources

About